Optimal inhalation profiles from dry powder inhalers - Optimal inhalation profiles from DPI

Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital0 个研究点目标入组 1 人开始时间: 2016年11月2日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 1

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Seven asthmatics without recent deterioration and regularly inhaling Turbuhaler or Diskus. Daily inhalation profiles and particle release from either DPI were measured at home for 2 weeks. Inhalation flow profile measured at home is highly reproducible, but tends to be weaker and shorter than that measured in the laboratory. Particle release from Turbuhaler was peak flow-dependent, but that from Diskus was not. The results confirm that rapid inhalations from the start are required when using a DPI.

研究设计

研究类型: Observational

入排标准

年龄范围: 18years-old 至 85years-old（—）
性别: All

入选标准

未提供

排除标准

•Those who fell into acute exacerbation at the time of study.

研究者

发起方

Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital

相似试验

已完成

不适用

Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung ObstructionPulmonary Disease, Chronic ObstructiveAsthma

NCT01033669Pfizer57

已完成

3 期

Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy StudyCystic Fibrosis

NCT00446680Syntara340

进行中（未招募）

不适用

ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic Fibrosis

EUCTR2007-001412-23-IEPharmaxis Pharmaceuticals Limited250

进行中（未招募）

1 期

ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 14.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic Fibrosis

EUCTR2006-004078-28-GBPharmaxis UK Limited250

进行中（未招募）

1 期

ong Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy StudyMedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisCystic Fibrosis

EUCTR2007-001412-23-DEPharmaxis Pharmaceuticals Limited340